FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387608511> ?p ?o ?g. }

• W4387608511 abstract "<div>AbstractPurpose:<p>Low-dose radiotherapy (LDRT) may enhance the synergistic antitumor effect of combined immunotherapy and stereotactic body radiotherapy (SBRT). The safety and efficacy of this novel triple-combination therapy were evaluated for the first time as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC).</p>Patients and Methods:<p>This prospective phase I study enrolled 29 patients and included a dose-escalation and dose-expansion phase. Patients received SBRT [30 Gray (Gy)/3f] to small lesions and LDRT (2 Gy/1f, 4 Gy/2f, or 10 Gy/5f) to a large lesion concurrently, followed by sintilimab (a programmed death-1 inhibitor). The primary endpoint was safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).</p>Results:<p>No dose-limiting toxicities were observed during the dose-escalation phase; 4 Gy/2f was the recommended LDRT dose. Median follow-up was 15.6 months. Treatment-related adverse events (TRAE) occurred in 96.6% (28/29) of patients [grade ≥ 3; 20.7% (6/29)]; 2 patients (6.9%) discontinued due to TRAEs. Seven patients experienced pneumonitis (grade 2, <i>n</i> = 6; grade 3, <i>n</i> = 1). Immune-related adverse events were noted in 58.6% (17/29) of patients. In patients with tumor assessment (<i>n</i> = 28), ORR and confirmed ORR were 60.7% and 57.1%, respectively. Median PFS was 8.6 months (95% confidence interval, 3.7–16.5), and median OS was not reached. Exploratory analyses suggested both expanded and newly emerging T-cell receptor clonotypes were associated with better PFS.</p>Conclusions:<p>The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with programmed death ligand-1–positive, driver gene–negative primary metastatic NSCLC.</p></div>" @default.
• W4387608511 created "2023-10-14" @default.
• W4387608511 creator A5000853510 @default.
• W4387608511 creator A5001501635 @default.
• W4387608511 creator A5003183189 @default.
• W4387608511 creator A5006117659 @default.
• W4387608511 creator A5009330754 @default.
• W4387608511 creator A5010431622 @default.
• W4387608511 creator A5011918071 @default.
• W4387608511 creator A5014692144 @default.
• W4387608511 creator A5020151887 @default.
• W4387608511 creator A5022128135 @default.
• W4387608511 creator A5025290762 @default.
• W4387608511 creator A5029180940 @default.
• W4387608511 creator A5031178757 @default.
• W4387608511 creator A5031458617 @default.
• W4387608511 creator A5033243059 @default.
• W4387608511 creator A5033411069 @default.
• W4387608511 creator A5038516631 @default.
• W4387608511 creator A5039053483 @default.
• W4387608511 creator A5043534663 @default.
• W4387608511 creator A5048923365 @default.
• W4387608511 creator A5053959485 @default.
• W4387608511 creator A5054862750 @default.
• W4387608511 creator A5059898483 @default.
• W4387608511 creator A5060211606 @default.
• W4387608511 creator A5061645783 @default.
• W4387608511 creator A5068240520 @default.
• W4387608511 creator A5070602766 @default.
• W4387608511 creator A5080438223 @default.
• W4387608511 creator A5081477925 @default.
• W4387608511 creator A5081518095 @default.
• W4387608511 creator A5081534462 @default.
• W4387608511 creator A5083184898 @default.
• W4387608511 creator A5083722152 @default.
• W4387608511 creator A5087045827 @default.
• W4387608511 creator A5087100048 @default.
• W4387608511 date "2023-10-13" @default.
• W4387608511 modified "2023-10-15" @default.
• W4387608511 title "Data from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1⁺ Non–Small Cell Lung Cancer Patients" @default.
• W4387608511 doi "https://doi.org/10.1158/1078-0432.c.6879425.v1" @default.
• W4387608511 hasPublicationYear "2023" @default.
• W4387608511 type Work @default.
• W4387608511 citedByCount "0" @default.
• W4387608511 crossrefType "posted-content" @default.
• W4387608511 hasAuthorship W4387608511A5000853510 @default.
• W4387608511 hasAuthorship W4387608511A5001501635 @default.
• W4387608511 hasAuthorship W4387608511A5003183189 @default.
• W4387608511 hasAuthorship W4387608511A5006117659 @default.
• W4387608511 hasAuthorship W4387608511A5009330754 @default.
• W4387608511 hasAuthorship W4387608511A5010431622 @default.
• W4387608511 hasAuthorship W4387608511A5011918071 @default.
• W4387608511 hasAuthorship W4387608511A5014692144 @default.
• W4387608511 hasAuthorship W4387608511A5020151887 @default.
• W4387608511 hasAuthorship W4387608511A5022128135 @default.
• W4387608511 hasAuthorship W4387608511A5025290762 @default.
• W4387608511 hasAuthorship W4387608511A5029180940 @default.
• W4387608511 hasAuthorship W4387608511A5031178757 @default.
• W4387608511 hasAuthorship W4387608511A5031458617 @default.
• W4387608511 hasAuthorship W4387608511A5033243059 @default.
• W4387608511 hasAuthorship W4387608511A5033411069 @default.
• W4387608511 hasAuthorship W4387608511A5038516631 @default.
• W4387608511 hasAuthorship W4387608511A5039053483 @default.
• W4387608511 hasAuthorship W4387608511A5043534663 @default.
• W4387608511 hasAuthorship W4387608511A5048923365 @default.
• W4387608511 hasAuthorship W4387608511A5053959485 @default.
• W4387608511 hasAuthorship W4387608511A5054862750 @default.
• W4387608511 hasAuthorship W4387608511A5059898483 @default.
• W4387608511 hasAuthorship W4387608511A5060211606 @default.
• W4387608511 hasAuthorship W4387608511A5061645783 @default.
• W4387608511 hasAuthorship W4387608511A5068240520 @default.
• W4387608511 hasAuthorship W4387608511A5070602766 @default.
• W4387608511 hasAuthorship W4387608511A5080438223 @default.
• W4387608511 hasAuthorship W4387608511A5081477925 @default.
• W4387608511 hasAuthorship W4387608511A5081518095 @default.
• W4387608511 hasAuthorship W4387608511A5081534462 @default.
• W4387608511 hasAuthorship W4387608511A5083184898 @default.
• W4387608511 hasAuthorship W4387608511A5083722152 @default.
• W4387608511 hasAuthorship W4387608511A5087045827 @default.
• W4387608511 hasAuthorship W4387608511A5087100048 @default.
• W4387608511 hasConcept C126322002 @default.
• W4387608511 hasConcept C143998085 @default.
• W4387608511 hasConcept C197934379 @default.
• W4387608511 hasConcept C203092338 @default.
• W4387608511 hasConcept C2776256026 @default.
• W4387608511 hasConcept C2777714996 @default.
• W4387608511 hasConcept C2778375690 @default.
• W4387608511 hasConcept C2779524853 @default.
• W4387608511 hasConcept C2780387249 @default.
• W4387608511 hasConcept C2989005 @default.
• W4387608511 hasConcept C509974204 @default.
• W4387608511 hasConcept C535046627 @default.
• W4387608511 hasConcept C71924100 @default.
• W4387608511 hasConcept C90924648 @default.
• W4387608511 hasConceptScore W4387608511C126322002 @default.
• W4387608511 hasConceptScore W4387608511C143998085 @default.
• W4387608511 hasConceptScore W4387608511C197934379 @default.
• W4387608511 hasConceptScore W4387608511C203092338 @default.
• W4387608511 hasConceptScore W4387608511C2776256026 @default.
• W4387608511 hasConceptScore W4387608511C2777714996 @default.

• next